首頁 > 市場調查報告書 > 製藥

循環系統

急性冠狀動脈症候群市場規模、佔有率和成長分析（按類型、診斷、治療、最終用戶和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1919088

急性冠狀動脈症候群市場規模、佔有率和成長分析（按類型、診斷、治療、最終用戶和地區分類）—2026-2033年產業預測

Acute Coronary Syndrome Market Size, Share, and Growth Analysis, By Type (Unstable Angina, ST-Elevation Myocardial Infarction (STEMI)), By Diagnosis (Blood Tests, Imaging), By Treatment, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月30日 | 出版商:

SkyQuest | 英文 195 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球急性冠狀動脈症候群市場規模預計在 2024 年達到 127 億美元，從 2025 年的 137.7 億美元成長到 2033 年的 262.5 億美元，在預測期（2026-2033 年）內複合年成長率為 8.4%。

全球急性冠狀動脈症候群市場正經歷顯著成長，其主要促進因素是與久坐不動的生活方式、肥胖、吸煙和高血壓等生活方式因素相關的心血管疾病患病率不斷上升。老化人口中心臟事件的發生率尤其高，進一步擴大了市場規模。透過教育宣傳活動提高公眾意識、採用創新診斷技術以及擴大急救醫療基礎設施等舉措，正在對患者的篩檢和治療產生積極影響。隨著新型抗凝血劑和抗血小板療法的出現，治療格局也在不斷發展，這得益於政府和私人部門對心臟護理（尤其是在開發中國家）投資的增加。然而，挑戰依然存在，包括治療成本不斷上漲、藥品核准法規環境嚴格以及農村地區醫療資源和熟練醫護人員短缺等問題。

全球急性冠狀動脈症候群市場促進因素

全球急性冠狀動脈症候群市場的主要促進因素之一是心血管疾病盛行率的不斷上升，而這主要受不健康飲食、缺乏運動和肥胖率上升等生活方式因素的影響。隨著越來越多的人面臨與急性冠狀動脈症候群相關的風險因素，對先進診斷工具和治療性介入的需求也在成長。此外，旨在改善患者預後和提高早期檢測能力的醫療技術和藥物的持續創新也進一步推動了市場成長。大眾對心血管健康的日益重視也對市場動態產生了積極影響，從而推動了對有效治療方法的需求。

全球急性冠狀動脈症候群市場面臨的限制因素

全球急性冠狀動脈症候群市場的主要限制因素之一是先進診斷和治療技術的高成本。包括支架植入、心臟手術和其他介入治療在內的最先進治療費用高昂，可能會限制很大一部分人群，尤其是在發展中地區，獲得這些療法的機會。此外，新藥和醫療設備嚴格的監管要求和漫長的核准流程也會阻礙創新解決方案進入市場。這種經濟壁壘會導致治療機會不均，最終影響患者預後，並抑制急性冠狀動脈症候群領域的整體市場成長。

全球急性冠狀動脈症候群市場趨勢

全球急性冠狀動脈症候群市場正日益受到個人化和精準醫療趨勢的影響。這一趨勢的核心在於透過先進的基因檢測、生物標記識別和全面的風險評估，為每位患者量身定做治療方案。從藥物治療到介入手術，醫療服務提供者透過個人化治療方案，旨在提高療效並最大限度地減少副作用。這種方法不僅能改善患者預後，還能促進標靶治療的研發，進而有助於急性冠狀動脈事件的長期管理與預防。隨著這一趨勢的不斷發展，預計將顯著重塑全球急性冠狀動脈症候群的治療模式。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

AstraZeneca
Bristol Myers Squibb
Sanofi
Pfizer Inc.
Bayer AG
Daiichi Sankyo Company, Ltd.
Eli Lilly and Company
Amgen Inc.
Novartis AG
Merck & Co.（MSD）
Johnson & Johnson（Janssen）
Roche（Genentech）
Boehringer Ingelheim
GlaxoSmithKline（GSK）
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
Dr. Reddy's Laboratories
Idorsia Pharmaceuticals
DalCor Pharmaceuticals
Novo Nordisk

結論與建議

簡介目錄

Product Code: SQMIG35I2488

Global Acute Coronary Syndrome Market size was valued at USD 12.7 billion in 2024 and is poised to grow from USD 13.77 billion in 2025 to USD 26.25 billion by 2033, growing at a CAGR of 8.4% during the forecast period (2026-2033).

The global acute coronary syndrome market is experiencing significant growth, driven by the rising prevalence of cardiovascular diseases linked to lifestyle factors such as sedentary habits, obesity, smoking, and hypertension. An aging population increases the incidence of cardiac events, particularly in regions with older demographics, enhancing market volume. Efforts to improve awareness through educational campaigns, innovative diagnostics, and upgraded emergency care infrastructure positively influence patient detection and treatment. The therapeutic landscape is evolving with new anticoagulants and antiplatelet therapies emerging, bolstered by increased investment in cardiac care from both government and private sectors, particularly in developing nations. However, challenges remain, including high treatment costs, strict regulatory environments for drug approvals, and disparities in healthcare access and skilled personnel in rural areas.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acute Coronary Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acute Coronary Syndrome Market Segments Analysis

Global Acute Coronary Syndrome Market is segmented by Type, Diagnosis, Treatment, End User and region. Based on Type, the market is segmented into Unstable Angina, ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI) and Others. Based on Diagnosis, the market is segmented into Blood Tests, Imaging, Stress Test and Others. Based on Treatment, the market is segmented into Medication, Surgery and Others. Based on End User, the market is segmented into Hospitals and Clinics, Diagnostic Centers, Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acute Coronary Syndrome Market

One of the key market drivers for the global acute coronary syndrome market is the increasing prevalence of cardiovascular diseases, which is largely fueled by lifestyle factors such as unhealthy diet, sedentary behavior, and rising levels of obesity. As more individuals experience risk factors associated with acute coronary syndrome, there is a heightened demand for advanced diagnostic tools and therapeutic interventions. Additionally, ongoing innovations in medical technology and pharmaceuticals aimed at improving patient outcomes and enhancing early detection capabilities further propel market growth. Increased awareness of cardiovascular health among the population also contributes positively to the market dynamics, driving demand for effective treatment options.

Restraints in the Global Acute Coronary Syndrome Market

One of the key market restraints for the global acute coronary syndrome market is the high cost of advanced diagnostic and therapeutic technologies. The expenses associated with cutting-edge treatments, including stents, cardiac surgery, and other interventional procedures, can limit accessibility for a significant portion of the population, particularly in developing regions. Additionally, stringent regulatory requirements and lengthy approval processes for new medications and devices can hinder market entry for innovative solutions. This financial barrier may lead to disparities in treatment availability, ultimately affecting patient outcomes and impeding overall market growth in the acute coronary syndrome sector.

Market Trends of the Global Acute Coronary Syndrome Market

The global acute coronary syndrome market is increasingly influenced by a shift towards personalized and precision medicine. This trend focuses on tailoring therapeutic strategies to individual patient profiles through advanced genetic testing, biomarker identification, and comprehensive risk assessment. By personalizing treatment options-ranging from medications to interventional procedures-healthcare providers aim to enhance efficacy while minimizing adverse effects. This approach not only improves patient outcomes but also fosters the development of targeted therapies, thereby facilitating long-term management and prevention of acute coronary events. As this trend gains momentum, it is expected to significantly reshape the landscape of acute coronary syndrome treatment globally.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment

Global Acute Coronary Syndrome Market Size by Type & CAGR (2026-2033)

Market Overview
Unstable Angina
ST-Elevation Myocardial Infarction (STEMI)
Non-ST-Elevation Myocardial Infarction (NSTEMI)
Others

Global Acute Coronary Syndrome Market Size by Diagnosis & CAGR (2026-2033)

Market Overview
Blood Tests
Imaging
Stress Test
Others

Global Acute Coronary Syndrome Market Size by Treatment & CAGR (2026-2033)

Market Overview
Medication
Surgery
Others

Global Acute Coronary Syndrome Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals and Clinics
Diagnostic Centers
Academic Institutes
Others

Global Acute Coronary Syndrome Market Size & CAGR (2026-2033)

North America (Type, Diagnosis, Treatment, End User)
- US
- Canada
Europe (Type, Diagnosis, Treatment, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Diagnosis, Treatment, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Diagnosis, Treatment, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Diagnosis, Treatment, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. (MSD)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (Janssen)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Genentech)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (GSK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Idorsia Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DalCor Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments